Immunology Investor Event

sanofi Playing to win with 10 novel molecules in 3 priority areas. 57 Gastroenterology Dermatology Atopic dermatitis Respiratory Asthma COPD EOE or UC Type 2 DUPIXENTⓇ (dupilumab) DUPIXENTⓇ (dupilumab) DUPIXENT® (dupilumab) amlitelimab (anti-OX40L) Injectables amlitelimab (anti-OX40L) anti-IL13/TSLP anti-TNFa/IL-23 anti-IL13/OX40L NanobodyⓇ VHH NanobodyⓇ VHH anti-IL13/OX40L NanobodyⓇ VHH itepekimab (anti-IL-33) NanobodyⓇ VHH non-beta IL-2 (Synthorin™M) Beyond Type 2 Orals rilzabrutinib (BTKI) IRAK4 degrader rilzabrutinib (BTKI) eclitasertib (RIPK1) ✓ Topical BTKi Eclitasertib is being developed in collaboration with Denali. All other listed agents are currently under clinical investigation and their safety and efficacy have not been evaluated by any regulatory authority. Except with respect to Dupixent in AD (age 6+) and Asthma, all indications listed are under investigation and not reviewed/approved by any regulatory authority 15 Immunology Investor Event

View entire presentation